MR angiography (MRA) is a relatively new alternative to CT angiography (CTA) for the evaluation of suspected pulmonary embolism (PE) and it even has one major advantage over CTA: it does not expose patients to ionizing radiation.

Intensive lipid-lowering therapy significantly reduces all-cause and cardiovascular mortality—but only for patients with low-density lipoprotein cholesterol (LDL-C) levels above 100 mg/dL, according to a meta-analysis published April 17 in JAMA.

Transfer times to an endovascular therapy-capable hospital are an average of 20 minutes slower during nighttime hours at one hub-and-spoke stroke network, possibly leading to a lower likelihood of those patients receiving thrombectomy.

While women are equally or overrepresented in clinical trials for hypertension, atrial fibrillation (AFib) and pulmonary arterial hypertension, they are underrepresented in clinical trials for heart failure, coronary artery disease and acute coronary syndrome, according to a new study published in the Journal of the American College of Cardiology.

SAN FRANCISCO, May 3, 2018 /PRNewswire/ — Eidos Therapeutics, Inc., a clinical stage biopharmaceutical company developing a novel oral therapy to treat transthyretin (TTR) amyloidosis (ATTR), today announced dosing of the first patient in the Phase 2 clinical trial of AG10 in patients with ATTR cardiomyopathy.

Abbott’s XIENCE Sierra, the newest generation of the company’s everolimus-eluting coronary stent, has been approved for national reimbursement in Japan.

The American Heart Association (AHA)/American Stroke Association (ASA) is revisiting its recently updated stroke guidelines after issuing a “correction” that removed several portions.

A new nationwide study from Japan highlighted the importance of timely ambulance arrival, showing that bystander defibrillation and cardiopulmonary resuscitation (CPR) for out-of-hospital cardiac arrest are essentially worthless if EMS response times are slower than 13 minutes and 11 minutes, respectively.